Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIERCE-HN
2023-505606-42-00Phase 3Authorised
- Sponsor
- AVEO Oncology
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) and metastatic head and neck squamous cell carcinoma (mHNSCC) comparing Ficlatuzumab + cetuximab with Placebo + cetuximab (2 arms). Primary endpoint: Overall survival. Planned start Apr 2024; status: authorised.
02
Drugs
ficlatuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)metastatic head and neck squamous cell carcinoma (mHNSCC)
Beyond the preview
Go deeper on 2023-505606-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505606-42-00.